News – Aug 02, 2017

Julius Clinical Awarded Two EU Grants for Clinical Studies

Zeist, 01 August 2017. Julius Clinical today announced that the European Commission granted the consortiums working on both the HIT-Cystic Fibrosis and Convince projects with financial funding to conduct these highly important clinical studies. Julius Clinical is a proud partner in these projects and will provide the operational services.   

HIT-CF
In the HIT-CF project, the aim is to bring personalised disease-modifying therapies to cystic fibrosis (CF) patients with ultra-rare CFTR mutation. These patients could otherwise never get access to such treatment. Once the unique concepts has been proven, the CF community can extend the  state-of-the-art methodology to all CF patients such that HIT-CF will impact the entire CF field.

H2020 CONVINCE
This consortium aims to determine the best possible dialysis treatment by comparing the conventional guideline based haemodialysis treatment versus high-dose haemodiafiltration. This will be done by carrying out a prospective randomized controlled clinical trial. The study will deliver an answer to the question about which intervention gives the best value for money. As such, it will be considered a landmark study, and the consortium will be allowed  to publish an “end of discussion” paper.